Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 54 articles:
HTML format
Text format



Single Articles


    March 2019
  1. JEONG KJ, Park SY, Cho KH, Sohn JS, et al
    Correction: The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
    Oncogene. 2019 Mar 29. pii: 10.1038/s41388-019-0769.
    PubMed     Text format     Abstract available


    February 2019
  2. JOHN B, Naczki C, Patel C, Ghoneum A, et al
    Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.
    Oncogene. 2019 Feb 14. pii: 10.1038/s41388-019-0728.
    PubMed     Text format     Abstract available


  3. INESS AN, Felthousen J, Ananthapadmanabhan V, Sesay F, et al
    The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.
    Oncogene. 2019;38:1080-1092.
    PubMed     Text format     Abstract available


    January 2019
  4. JING Y, Zhang Y, Zhu H, Zhang K, et al
    Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer.
    Oncogene. 2019 Jan 7. pii: 10.1038/s41388-018-0644.
    PubMed     Text format     Abstract available


    December 2018
  5. MOTOHARA T, Masuda K, Morotti M, Zheng Y, et al
    An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
    Oncogene. 2018 Dec 19. pii: 10.1038/s41388-018-0637.
    PubMed     Text format     Abstract available


  6. GRABOSCH S, Bulatovic M, Zeng F, Ma T, et al
    Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
    Oncogene. 2018 Dec 5. pii: 10.1038/s41388-018-0581.
    PubMed     Text format     Abstract available


    November 2018
  7. ZHAO L, Wang W, Xu L, Yi T, et al
    Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0577.
    PubMed     Text format     Abstract available


    October 2018
  8. MCLEAN K, Tan L, Bolland DE, Coffman LG, et al
    Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0523.
    PubMed     Text format     Abstract available


    September 2018
  9. ZHONG Y, Yang S, Wang W, Wei P, et al
    The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer.
    Oncogene. 2018 Sep 28. pii: 10.1038/s41388-018-0512.
    PubMed     Text format     Abstract available


    August 2018
  10. SUN J, Cai X, Yung MM, Zhou W, et al
    miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
    Oncogene. 2018 Aug 30. pii: 10.1038/s41388-018-0459.
    PubMed     Text format     Abstract available


    July 2018
  11. HODGKINSON K, Forrest LA, Vuong N, Garson K, et al
    GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer.
    Oncogene. 2018 Jul 4. pii: 10.1038/s41388-018-0377.
    PubMed     Text format     Abstract available


  12. ZHOU W, Sun W, Yung MMH, Dai S, et al
    Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.
    Oncogene. 2018;37:3981-3997.
    PubMed     Text format     Abstract available


    June 2018
  13. OZES AR, Pulliam N, Ertosun MG, Yilmaz O, et al
    Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Oncogene. 2018;37:3589-3600.
    PubMed     Text format     Abstract available


    May 2018
  14. AL HABYAN S, Kalos C, Szymborski J, McCaffrey L, et al
    Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer.
    Oncogene. 2018 May 23. pii: 10.1038/s41388-018-0317.
    PubMed     Text format     Abstract available


  15. GABBASOV R, Xiao F, Howe CG, Bickel LE, et al
    NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice.
    Oncogene. 2018 May 18. pii: 10.1038/s41388-018-0296.
    PubMed     Text format     Abstract available


  16. RADA M, Nallanthighal S, Cha J, Ryan K, et al
    Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
    Oncogene. 2018 May 17. pii: 10.1038/s41388-018-0297.
    PubMed     Text format     Abstract available


  17. BERNS K, Caumanns JJ, Hijmans EM, Gennissen AMC, et al
    ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Oncogene. 2018 May 15. pii: 10.1038/s41388-018-0300.
    PubMed     Text format     Abstract available


    April 2018
  18. DORAYAPPAN KDP, Wanner R, Wallbillich JJ, Saini U, et al
    Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.
    Oncogene. 2018 Apr 11. pii: 10.1038/s41388-018-0189.
    PubMed     Text format     Abstract available


    February 2018
  19. MITAMURA T, Pradeep S, McGuire M, Wu SY, et al
    Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).
    Oncogene. 2018;37:722-731.
    PubMed     Text format     Abstract available


  20. LIU Y, Zhou H, Zhu R, Ding F, et al
    SPSB3 targets SNAIL for degradation in GSK-3beta phosphorylation-dependent manner and regulates metastasis.
    Oncogene. 2018;37:768-776.
    PubMed     Text format     Abstract available


  21. LADANYI A, Mukherjee A, Kenny HA, Johnson A, et al
    Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
    Oncogene. 2018 Feb 5. pii: 10.1038/s41388-017-0093.
    PubMed     Text format     Abstract available


    January 2018
  22. AKHTER MZ, Sharawat SK, Kumar V, Kochat V, et al
    Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0106.
    PubMed     Text format     Abstract available


  23. GHANNAM-SHAHBARI D, Jacob E, Kakun RR, Wasserman T, et al
    PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0040.
    PubMed     Text format     Abstract available


  24. RUSSO A, Czarnecki AA, Dean M, Modi DA, et al
    PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0097.
    PubMed     Text format     Abstract available


  25. GRITHER WR, Divine LM, Meller EH, Wilke DJ, et al
    TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.
    Oncogene. 2018 Jan 19. pii: 10.1038/s41388-017-0043.
    PubMed     Text format     Abstract available


  26. NAGARAJ AB, Wang QQ, Joseph P, Zheng C, et al
    Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
    Oncogene. 2018;37:403-414.
    PubMed     Text format     Abstract available


  27. CORKERY DP, Clarke LE, Gebremeskel S, Salsman J, et al
    Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.
    Oncogene. 2018;37:174-184.
    PubMed     Text format     Abstract available


    October 2017
  28. WANG J, Kho DH, Zhou JY, Davis RJ, et al
    MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
    Oncogene. 2017;36:5939-5947.
    PubMed     Text format     Abstract available


    September 2017
  29. BIAN X, Gao J, Luo F, Rui C, et al
    PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Oncogene. 2017 Sep 25. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  30. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  31. YAMAGUCHI H, Du Y, Nakai K, Ding M, et al
    EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  32. GUO H, Zhu Q, Yu X, Merugu SB, et al
    Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.
    Oncogene. 2017;36:5098-5109.
    PubMed     Text format     Abstract available


    August 2017
  33. SOMASAGARA RR, Spencer SM, Tripathi K, Clark DW, et al
    RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
    Oncogene. 2017 Aug 14. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    June 2017
  34. TO SKY, Mak ASC, Eva Fung YM, Che CM, et al
    beta-catenin downregulates Dicer to promote ovarian cancer metastasis.
    Oncogene. 2017 Jun 26. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  35. KLYMENKO Y, Kim O, Loughran E, Yang J, et al
    Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    May 2017
  36. ZHAO J, Wang Y, Mu C, Xu Y, et al
    MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
    Oncogene. 2017 May 1. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    April 2017
  37. NIU N, Mercado-Uribe I, Liu J
    Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells.
    Oncogene. 2017 Apr 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    March 2017
  38. SHANG Y, He J, Wang Y, Feng Q, et al
    CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
    Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  39. BASULI D, Tesfay L, Deng Z, Paul B, et al
    Iron addiction: a novel therapeutic target in ovarian cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  40. COMISSO E, Scarola M, Rosso M, Piazza S, et al
    OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  41. GUPTA R, Yang Q, Dogra SK, Wajapeyee N, et al
    Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    February 2017
  42. HWANG MH, Cho KH, Jeong KJ, Park YY, et al
    RCP induces Slug expression and cancer cell invasion by stabilizing beta1 integrin.
    Oncogene. 2017;36:1102-1111.
    PubMed     Text format     Abstract available


  43. HARJES U, Bridges E, Gharpure KM, Roxanis I, et al
    Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.
    Oncogene. 2017;36:912-921.
    PubMed     Text format     Abstract available


  44. LAU TS, Chan LK, Wong EC, Hui CW, et al
    A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFalpha-TGFalpha-EGFR.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    January 2017
  45. ZHAO L, Ji G, Le X, Luo Z, et al
    An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.
    Oncogene. 2017 Jan 23. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    December 2016
  46. MODI DA, Tagare RD, Karthikeyan S, Russo A, et al
    PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Oncogene. 2016 Dec 19. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  47. GURLER MAIN H, Xie J, Muralidhar GG, Elfituri O, et al
    Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma.
    Oncogene. 2016 Dec 12. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    November 2016
  48. WILSON C, Qiu L, Hong Y, Karnik T, et al
    The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  49. DIMITROVA N, Nagaraj AB, Razi A, Singh S, et al
    InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer.
    Oncogene. 2016 Nov 7. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    October 2016
  50. MATSUURA K, Huang NJ, Cocce K, Zhang L, et al
    Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  51. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  52. WITT AE, Lee CW, Lee TI, Azzam DJ, et al
    Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    September 2016
  53. FANG D, Chen H, Zhu JY, Wang W, et al
    Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2016 Sep 12. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  54. DE CIAN MC, Pauper E, Bandiera R, Vidal VP, et al
    Amplification of R-spondin1 signaling induces granulosa cell fate defects and cancers in mouse adult ovary.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: